Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (August 2021)

71 slides from Marinus Pharmaceuticals's investor presentation, Aug 17, 2021

  1. Slide 1: Corporate Presentation August 2021

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Corporate Presentation August 2021

  2. Slide 2: Safe Harbor Statement

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 2 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management m

  3. Slide 3: Ganaxolone Targets Synaptic & Extrasynaptic GABA A Receptors

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 3 Ganaxolone (GNX) Targets Synaptic & Extrasynaptic GABA A Receptors Ganaxolone a positive allosteric GABA A receptor modulator with a well - defined MOA designed to treat patients suffering from seizure disorders. GNX is designed to modulate both

  4. Slide 4: Evaluation of IV and Oral Opportunities Building Upon Status Epilepticus

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Evaluation of IV and Oral Opportunities Building Upon Status Epilepticus (SE) Maximizing Value for Orphan Epilepsies • Expand clinical opportunities to broader status epilepticus indications • Build U.S. commercial strategy • Execute global develo

  5. Slide 5: Ganaxolone Development Pipeline

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 5 Ganaxolone Development Pipeline

  6. Slide 6: Orphan Epilepsy Oral Ganaxolone Franchise

    Orphan Epilepsy Oral Ganaxolone Franchise

  7. Slide 7: CDKL5 Deficiency Disorder

    CDKL5 Deficiency Disorder “CDKL5 is painful. It’s a hard, sad at times, thing that we face. When you have a relationship with people like Marinus and their researchers, you are able to help be a driving force behind that work. - Karen Utley, Mother to Samantha, President of International Foundation

  8. Slide 8: CDKL5 Deficiency Disorder (CDD)

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Cause • Mutation of the cyclin - dependent kinase - like 5 ( CDKL5 ) gene, located on the X chromosome Symptoms • Early - onset, treatment refractory seizures, & severe neuro - developmental delay • Most can’t walk, talk or care for themselves • S

  9. Slide 9: Completed Global Phase 3 Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 9 Completed Global Phase 3 Trial Design Baseline 6 weeks Historical Control 8 weeks Double - Blind Phase Open - Label Phase Maintenance 13 weeks Titration 4 weeks Open - Label Phase ► Trial Details • Evaluated the use of oral ganaxolone in childre

  10. Slide 10: Marigold Baseline Clinical Characteristics

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 10 Marigold Baseline Clinical Characteristics Characteristic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Baseline Primary Seizure Frequency, per 28 days (median, IQR) 49.2 ( 18.7 – 120.0) 54.0 (31.3 – 147.3) - Number of AED Medications Taken Pr

  11. Slide 11: Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 11 Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction and Secondary Endpoint for Seizure Severity Caregiver Global Impression of Change in Seizure Intensity / Duration (CGI - CSID) Ganaxolone Placebo 0 10 20 30 40 M e d i a n P e r

  12. Slide 12: Marigold Cumulative Response Curve

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 12 Marigold Cumulative Response Curve 0% 5 10 15 20 25 30 35 40 45 50 0 10 20 30 40 50 60 70 80 90 100 Percent Reduction 28-day Frequency of Major Motor Seizures % o f P a t i e n t s Ganaxolone Placebo 24.5% 9.8% p = 0.064 a = 14.7 (-4.7, 33.8) b

  13. Slide 13: Consistent Efficacy Signal Across the Broader CDD Population

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Consistent Efficacy Signal Across the Broader CDD Population ► Ganaxolone demonstrated a similar efficacy signal across multiple subgroups related to baseline demographics and seizure frequency • Supports beneficial effect in the U.S. patient popu

  14. Slide 14: Phase 3 Safety Summary

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 14 Phase 3 Safety Summary Treatment Emergent Adverse Events (TEAE) Preferred Term Placebo (n=51) Ganaxolone (n=50) Any TEAE, n (%) 45 (88.2) 43 (86.0) Somnolence 8 (15.7) 18 (36.0) Pyrexia 4 (7.8) 9 (18.0) Upper Respiratory Tract Infection 3 (5.9)

  15. Slide 15: Potential to Provide Durable Seizure Improvements in Open Label Extension

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 15 Ganaxolones Potential to Provide Durable Seizure Improvements in the Open Label Extension • Seizures associated with CDD are often refractory to treatment with existing AEDs and improvements may be short - lived (<3 months) 1 • Preliminary anal

  16. Slide 16: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 16 Average Ganaxolone Levels Correlate with Seizure Reduction • Logarithms of plasma GNX level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High GNX level groups had an average GNX

  17. Slide 17: PK Analysis: Adult Focal Onset Seizure Trial vs. Marigold

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 17 PK Analysis: Adult Focal Onset Seizure Trial vs. Marigold Age Group AUC 24 (ng* hr /mL) C min (ng/mL) C max (ng/mL) 2 to <6 years 3903 85 247 6 to <12 years 3998 84 269 12 to <18 yrs 4106 84 293 ≥18 years 4100 84 292 Abbreviations: AUC 24 =24 -

  18. Slide 18: CDD Regulatory Timeline

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 18 CDD Regulatory Timeline ► Submitted New Drug Application (NDA) to FDA for ganaxolone for the treatment of seizures associated with CDD in July 2021 ► The NDA includes a request for Priority Review, which, if granted, accelerates completion of t

  19. Slide 19: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck , President &

  20. Slide 20: Tuberous Sclerosis Complex (TSC)

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Cause • Defect or mutation of TSC1 and/or TSC2 genes Symptoms • Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Incidence Prevalence • 1:6,000 live births • ~25K - 40K refractory TSC patients in the U.S.* Tre

  21. Slide 21: TSC Phase 2 Open-Label Clinical Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Baseline (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol 21 TSC - Phase 2 Open - Label Clinical Trial Design Base

  22. Slide 22: Percent Reduction in TSC-associated Seizure Frequency

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 22 Percent Reduction in TSC - associated Seizure Frequency -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 P e r c e n t r e d u c t i o n i n T S C - a s s o c i a t e d s e i z u r e f r e q u e n c y =median 16.6% -20 0 20 40 60 80 100 Percent redu

  23. Slide 23: Phase 2 Secondary and Exploratory Analyses

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 23 Phase 2 Secondary and Exploratory Analyses Intent to Treat (n=23) +Cannabidiol (n=12) +Everolimus (n=11) 0 5 10 15 20 25 30 35 40 45 50 36.4 25.0 30.4 P e r c e n t o f p a t i e n t s Proportion of patients with a ≥50% reduction in TSC - assoc

  24. Slide 24: TSC Phase 2 Comparison to Marigold Study

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 24 TSC Phase 2 Comparison to Marigold Study (CDD Phase 3) *Double - blind ganaxolone subjects *

  25. Slide 25: Safety

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 25 Safety ► Ganaxolone was generally well - tolerated with somnolence reported as the most common adverse event consistent with previous studies • Four patients (17.4%) discontinued due to adverse events Preferred Term Ganaxolone (n=23) Any TEAE,

  26. Slide 26: Proposed Phase 3 TSC Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I ► Trial details • Evaluates the use of oral ganaxolone in children and adults with seizures associated with TSC • Global, double - blind, placebo - controlled clinical trial • Aims to enroll ~160 total patients between the ages of 1 and 65 (1:1 ra

  27. Slide 27: Phase 3 TSC Clinical Trial Enhancements

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 27 Phase 3 TSC Clinical Trial Enhancements ► Adjustment to weekly titration schedule • Aimed to further improve tolerability in TSC patients ► Seizure classification • Ensure seizures are being accurately documented and reliably counted through on

  28. Slide 28: Formulation Development

    Formulation Development Oarinus

  29. Slide 29: Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 29 Efforts to Improve Ganaxolone Exposure in Chronic Epilepsies ► Dosing regimen: Marigold trial was the first Phase 3 trial of ganaxolone to evaluate three times a day (TID) dosing • Predicted pharmacokinetic (PK) curves for TID and two times a d

  30. Slide 30: Ganaxolone Formulation Work in Progress for Second Generation Candidate

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 30 Ganaxolone Formulation Work in Progress for Second Generation Candidate Step down IV to oral Pediatric Dosing IV Dosing Oral Dosing • Exploring opportunities to improve bioavailability and PK profile • Potential expansion into new indications a

  31. Slide 31: Commercial Opportunity

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Commercial Opportunity

  32. Slide 32: Commercialization Preparedness

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 32 Commercialization Preparedness Refining and Optimizing Value Proposition for Market Testing with key stakeholders – Providers, Payers Developing organizational and infrastructure needs – home office, field, systems and processes Readying supply

  33. Slide 33: Key Findings from Recently Conducted Market Research

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 33 Key Findings from Recently Conducted Market Research Show that Ganaxolone is Well Suited for Broad Clinical Adoption Across Indications Awareness Mechanism of Action TPP Reactions Primary Usage Drivers Source: ZS Associates Primary Research and

  34. Slide 34: Acute Seizure Disorders Intravenous (IV) Ganaxolone Franchise

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Franchise

  35. Slide 35: Status Epilepticus

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus

  36. Slide 36: Status Epilepticus (SE): Definition and Epidemiology

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 36 Status Epilepticus (SE): Definition and Epidemiology Background ► Prolonged continuous seizures ► Heterogenous patient population with various etiologies, including glioblastoma, vascular disease, encephalitis, drug or alcohol withdrawal or ove

  37. Slide 37: Goals of a New Therapy for the Treatment of SE

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 37 Goals of a New Therapy for the Treatment of SE Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE) 1 st line 2 nd line IV AED’s (antiepileptic drugs) 3 rd line IV Anesthetics Super Refractory Status Epileptic

  38. Slide 38: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 38 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers fol

  39. Slide 39: Phase 2 Refractory Status Epilepticus Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 39 Phase 2 Refractory Status Epilepticus Trial Design Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus

  40. Slide 40: Patient Demographics of Phase 2 Trial

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 40 Patient Demographics of Phase 2 Trial 8 males, 9 females Mean age: 57 years old (range: 23 - 88) 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE→NCSE 7 (41%) yes, 10 (59%) no 17 patients enrolled Types of SE History of Epilepsy Mean # of failed 2nd - li

  41. Slide 41: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 41 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free through 24 hours from infusion initiation (investigator det

  42. Slide 42: PK/PD Relationship and Rationale for Target Dose

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 42 PK/PD Relationship and Rationale for Target Dose Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduc

  43. Slide 43: IV Ganaxolone Safety Summary

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 43 IV Ganaxolone Safety Summary Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment perio d Data presented at AES 2019 AE: adverse event / SAE: serious adverse ev

  44. Slide 44: Overview of U.S. Phase 3 RSE RAISE Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 44 Overview of U.S. Phase 3 RSE RAISE Trial Design Trial design • Randomized, placebo - controlled clinical trial Target patient population • Status epilepticus patients (n=124) who have failed benzodiazepines and ≥ 2 IV AEDs Dosing • 36 - hour in

  45. Slide 45: RSE Phase 3 RAISE Clinical Planning

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 45 RSE Phase 3 RAISE Clinical Planning • 1:1 randomized, double - blind, placebo - controlled trial • Failure of a benzodiazepine and 2 second - line IV AEDs • 3 - minute bolus, 36 - hour infusion, 12 - hour taper • ~125 randomized patients • ~80

  46. Slide 46: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 46 RAISE Trial Sites Standard of Care Progression to IV Anesthesia ► Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than

  47. Slide 47: Commercial Opportunity

    Commercial Opportunity OmaRINUS

  48. Slide 48: Quantifying the Significant Clinical and Economic Burden of RSE

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 48 Quantifying the Significant Clinical and Economic Burden of RSE The Phase 3 trial of ganaxolone in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation to IV anesthetics, and downstream associated clinical ou

  49. Slide 49: High Cost of Care Currently Associated with RSE Population

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 49 High Cost of Care Currently Associated with RSE Population Ganaxolone may provide an opportunity to reduce hospital costs and save lives by altering how medicine is practiced Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (

  50. Slide 50: Status Epilepticus Development Plan

    Status Epilepticus Development Plan

  51. Slide 51: Status Epilepticus Patient Populations & Development Plan

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 51 Status Epilepticus Patient Populations & Development Plan Convulsive SE Non - Convulsive SE/ Focal SE (55% of total SE population) 1 Benzodiazepines IV AED’s IV Anesthetics IV AED’s IV Anesthetics ESE Phase 2 Trial ICU / Neuro ICU time Establis

  52. Slide 52: Additional Commercial Opportunities Along SE Continuum

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 52 Additional Commercial Opportunities Along SE Continuum Potential to leverage future hospital sales force to address > 3x patient population in ESE & SRSE 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin N

  53. Slide 53: Treatment of Refractory Status Epilepticus: RAISE vs. RAISE II

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 53 Emergency Room ICU Tertiary Center ICU Treatment of Refractory Status Epilepticus: RAISE vs. RAISE II Failure of Benzodiazepines and Initial Second Line AEDs (RAISE II) Failure of Benzodiazepines and Two or More Second Line AEDs (RAISE) RAISE I

  54. Slide 54: Proposed Phase 3 Trial in Refractory SE (RAISE II)

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I ► Trial Goals: • Support potential European approval in RSE • Potential indication expansion opportunity (relative to the RAISE study population) 54 Proposed Phase 3 Trial in Refractory SE (RAISE II) Trial Attributes Trial Population Failure of be

  55. Slide 55: Established Status Epilepticus – Potential Use of Ganaxolone in Emergency Room

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 55 Emergency Room ICU Tertiary Center ICU Established Status Epilepticus – Potential Use of Ganaxolone in Emergency Room Key trial points: • Patients with convulsive status epilepticus • new dosing paradigm – bolus and short infusion time (2 - 24

  56. Slide 56: Established Status Epilepticus – Proposed ESE Clinical Trial Design

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 56 Established Status Epilepticus – Potential Use of Ganaxolone in Emergency Room Failed benzodiazepine Open B olus IV ganaxolone infusion Screening Double - blind treatment (2 - 24h) Failed benzodiazepine Randomization 1:1 Standard of care IV AED

  57. Slide 57: Financial Update

    Financial Update OMaRINUS

  58. Slide 58: European Collaboration Agreement Overview

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I European Collaboration Agreement Overview European collaboration with Orion Corporation , a global, Finland - based pharmaceutical company dedicated to the development of innovative therapeutics including a focus on neurological disorders Orion re

  59. Slide 59: Financial Overview: Q2 2021

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview: Q2 2021 Analyst Coverage * : • Cantor Fitzgerald: Alethia Young • Cowen: Joseph Thome, Ph.D. • H.C. Wainwright & Co: Douglas Tsao • Jefferies: Andrew Tsai • JMP Securities: Jason N. Butler, Ph.D. • Ladenburg Thalmann : Michael

  60. Slide 60: Credit Financing Overview

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I Credit Financing Overview Credit financing agreement with Oaktree Capital Management , a leader among investment managers specializing in alternative investments Financing has potential to provide incremental cash of up to $125 million total throu

  61. Slide 61: BARDA Contract – Refractory Status Epilepticus

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 61 BARDA Contract – Refractory Status Epilepticus Key Contract Parameters ► Biomedical Advanced Research and Development Authority (BARDA) to contribute $21 million in base contract to support the Phase 3 RAISE clinical trial in RSE and preclinica

  62. Slide 62: Intellectual Property

    Intellectual Property

  63. Slide 63: Multiple Layers Of Potential Protection

    ©2021 Marinus Pharmaceuticals. CONFIDENTIAL. All Rights Reserved I 63 Multiple Layers Of Potential Protection Patent/Patent Applications Expiration Date IV formulations containing exclusively in - licensed proprietary Captisol ® product 2033 SE – patent application pending on IV formulations and met

  64. Slide 64: Thank You

    fe tek Thank You

  65. Slide 65: Appendix

    Appendix O MARINUS

  66. Slide 66: CDKL5 Deficiency Disorder

    CDKL5 Deficiency Disorder OmaRINUS

  67. Slide 67: Subject Baseline Demographics & Country Enrollment in Marigold Study

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 67 Subject Baseline Demographics & Country Enrollment in Marigold Study (CDD) Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2)

  68. Slide 68: Responder Analysis – Marigold Study

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 68 Responder Analysis – Marigold Study Percent Reductions in Major Motor Seizure Frequency 25% 50% 75% 0 20 40 60 80 100 Percent Reduction 28-day Frequency of Major Motor Seizures % o f P a t i e n t s Ganaxolone Placebo 57.1% 23.5% 24.5% 9.8% 10.

  69. Slide 69: Status Epilepticus

    Status Epilepticus OMaRiNUS

  70. Slide 70: Details on Baseline Patient Characteristics for Phase 2 SE Trial

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 70 NCSE: Non - convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid Details on Baseline Patient Characteristics for Phase 2 SE Trial

  71. Slide 71: Potential Launch Into the Hospital Setting

    ©2021 Marinus Pharmaceuticals. All Rights Reserved I 71 Potential Launch Into the Hospital Setting Designed to be Driven by Data, Customer Collaboration & Protocolization of Ganaxolone in RSE • Phase 3 data to support clinical adoption and budget model • Clear clinical benefit eg, SE cessation, IV e

Marinus Pharmaceuticals — Investor Presentation (August 2021) on 6ix